Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers

Journal of Virology

Volumn 88, Issue 5, 2014, Pages 2799-2809

  Lai, Jennifer I ^a   Licht, Anna F ^b   Dugast, Anne Sophie ^b   Suscovich, Todd ^b   Choi, Ickwon ^c   Bailey Kellogg, Chris ^c   Alter, Galit ^b   Ackerman, Margaret E ^a,d  

^a DARTMOUTH COLLEGE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Dartmouth Department of Computer Science_Dartmouth College   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2 ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLELE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ALLELES; ANTIBODY SPECIFICITY; CLUSTER ANALYSIS; CYTOTOXICITY, IMMUNOLOGIC; HIV ANTIBODIES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HLA-B ANTIGENS; HUMANS; IMMUNOGLOBULIN G; MICROARRAY ANALYSIS; RECEPTORS, IGG; VIRAL PROTEINS;

EID: 84896730604     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03130-13     Document Type: Article

References (37)

1. Baker BM, Block BL, Rothchild AC, Walker BD. 2009. Elite control of HIV infection: implications for vaccine design. Expert Opin. Biol. Ther. 9:55-69. http://dx.doi.org/10.1517/14712590802571928.
2. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB. 2007. A wholegenome association study of major determinants for host control of HIV-1. Science 317:944-947. http://dx.doi.org/10.1126/science.1143767.
3. Carrington M, Walker BD. 2012. Immunogenetics of spontaneous control of HIV. Annu. Rev. Med. 63:131-145. http://dx.doi.org/10.1146 /annurev-med-062909-130018.
4. Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, Brander C, Coovadia H, Walker BD, Heckerman D, Goulder PJR. 2010. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J. Virol. 84:9879-9888. http://dx.doi.org/10.1128/JVI .00320-10.
5. Pereyra F, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557. http://dx .doi.org/10.1126/science.1195271.
6. Kosmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, Deeks SG, Pereyra F, Carrington M, Walker BD, Chakraborty AK. 2010. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465:350-354. http://dx.doi.org/10.1038/nature08997.
7. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-571. http://dx.doi.org/10.1086 /526786.
8. Xie J, Lu W, Samri A, Costagliola D, Schnuriger A, da Silva BC, Blanc C, Larsen M, Theodorou I, Rouzioux C, Autran B, ALT-ANRS-CO15 Study Group. 2010. Distinct differentiation profiles of HIV-Gag and Nefspecific central memory CD8T cells associated with HLA-B57/5801 and virus control. AIDS 24:2323-2329. http://dx.doi.org/10.1097/QAD .0b013e32833e5009.
9. Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, Dugast AS, Heizen EL, Ercan A, Choi I, Streeck H, Nigrovic PA, Bailey-Kellogg C, Scanlan C, Alter G. 2013. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123:2183-2192. http://dx.doi.org/10.1172/JCI65708.
10. Ackerman ME, Dugast AS, McAndrew EG, Tsoukas S, Licht AF, Irvine DJ, Alter G. 2013. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgammaR2a and FcgammaR2b. J. Virol. 87:5468-5476. http://dx.doi.org/10.1128/JVI.03403-12.
11. Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP. 2010. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res. Hum. Retroviruses 26:445-458. http://dx.doi.org/10.1089/aid .2009.0223.
12. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J. 1996. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157:2168-2173. http://www .jimmunol.org/content/157/5/2168.
13. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J. 1999. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J. Infect. Dis. 180:1338-1341. http://dx.doi.org/10.1086/314988.
14. Lal RB, Heiba IM, Dhawan RR, Smith ES, Perine PL. 1991. IgG subclass responses to human immunodeficiency virus-1 antigens:lack of IgG2 response to gp41 correlates with clinical manifestation of disease. Clin. Immunol. Immunopathol. 58:267-277. http://dx.doi.org /10.1016/0090-1229(91)90141-V.
15. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Delfraissy JF. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:897-906. http://dx.doi.org/10.1097/QAD.0b013e328329f97d.
16. French MA, Center RJ, Wilson KM, Fleyfel I, Fernandez S, Schorcht A, Stratov I, Kramski M, Kent SJ, Kelleher AD. 2013. Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers. AIDS 27:519-528. http://dx.doi.org/10 .1097/QAD.0b013e32835cb720.
17. Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, Haynes BF, Jean-François Delfraissy J-F, Saez-Cirion A, Ferrari G. 2013. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 t cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS One 8(9):e74855. http://dx.doi.org/10.1371 /journal.pone.0074855.
18. Ackerman ME, Dugast AS, Alter G. 2012. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu. Rev. Med. 63:113-130. http://dx.doi.org/10.1146/annurev-med-050310 -085221.
19. Banks ND, Kinsey N, Clements J, Hildreth JE. 2002. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res. Hum. Retroviruses 18:1197-1205. http://dx.doi.org/10.1089/08892220260387940.
20. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincelette J, Menezes J, Ahmad A. 2001. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21:227-233. http://dx.doi .org/10.1023/A:1011087132180.
21. Asmal M, Sun Y, Lane S, Yeh W, Schmidt SD, Mascola JR, Letvin NL. 2011. Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J. Virol. 85:5465-5475. PMCID:3094968. http://dx.doi.org/10.1128/JVI.00313-11.
22. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M, Jr, Carville A, Mansfield KG, Lifson JD, Li W, Desrosiers RC, Johnson RP, Evans DT 2012. ADCC develops over time during persistent infection with liveattenuated SIV and is associated with complete protection against SIV-(mac)251 challenge. PLoS Pathog. 8(8):e1002890. http://dx.doi.org/10 .1371/journal.ppat.1002890.
23. Hidajat R, Xiao P, Zhou Q., Venzon D, Summers LE, Kalyanaraman VS, Montefiori DC, Robert-Guroff M. 2009. Correlation of vaccineelicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 83:791-801. http://dx.doi.org/10.1128/JVI.01672-08.
24. Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M. 2005. Vaccine-elicited antibodies mediate antibodydependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174:2185-2189. http://www.jimmunol.org/content/174/4/2185.
25. Forthal DN, Gilbert PB, Landucci G, Phan T. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178:6596-6603. http://www.jimmunol.org /content/178/10/6596.
26. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF. 2012. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86:11521-11532. http://dx.doi.org/10.1128 /JVI.01023-12.
27. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286. http://dx.doi.org/10.1056/NEJMoa1113425.
28. Nimmerjahn F, Ravetch JV. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310:1510-1512. http://dx.doi.org/10.1126/science.1118948.
29. McAndrew EG, Dugast AS, Licht AF, Eusebio JR, Alter G, Ackerman ME. 2011. Determining the phagocytic activity of clinical antibody samples. J. Vis. Exp. 2011(57):e3588. http://dx.doi.org/10.3791/3588.
30. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G. 2011. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366:8-19. http://dx.doi.org/10.1016/j.jim.2010.12.016.
31. Gómez-Román VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M. 2006. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308:53-67. http://dx.doi.org/10.1016/j.jim.200 5.09.018.
32. Brown EP, Licht AF, Dugast AS, Choi I, Bailey-Kellogg C, Alter G, Ackerman ME 2012. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods 386:117-123. http://dx.doi.org/10.1016/j.jim.2012.09.007.
33. Moldt B, Schultz N, Dunlop DC, Alpert MD, Harvey JD, Evans DT, Poignard P, Hessell AJ, Burton DR. 2011. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV. J. Virol. 85(20):10572-10581. http://dx.doi.org/10.1128/JVI.05541-11.
34. Terai I, Kobayashi K, Vaerman JP, Mafune N. 2006. Degalactosylated and/or denatured IgA, but not native IgA in any form, bind to mannosebinding lectin. J. Immunol. 177(3):1737-1745. http://www.jimmunol.org /content/177/3/1737.
35. Martinez V, Costagliola D, Bonduelle O, Ng̀o N, Schnuriger A, Theodorou I, Clauvel JP, Sicard D, Agut H, Debré P, Rouzioux C, Autran B, Asymptomatiques à Long Terme Study Group. 2005. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J. Infect. Dis. 191:2053-2063. http://dx.doi.org/10.1086/430320.
36. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, Sicard D, Clauvel JP, Agut H, Costagliola D, Rouzioux C, French Asymptomatic Long-Term Study Group. 2001. HIV type 1-specific IgG2 antibodies:markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res. Hum. Retroviruses 17:1435-1446. http://dx.doi.org/10.1089/088922201753197105.
37. Pandey JP, French MA. 1996. GM phenotypes influence the concentrations of the four subclasses of immunoglobulin G in normal human serum. Hum. Immunol. 51:99-102. http://dx.doi.org/10.1016/S0198-8859 (96)00205-4.